Aradigm's SmartMist Shows Promise
Optimizing aerosol inhalation by controlling flow rate and inspiration timing can significantly improve pulmonary drug delivery, reported Stephen Farr, a member of US company Aradigm's scientific advisory board, speaking at the American Association of Pharmaceutical Scientists in San Diego, California.
Dr Farr was commenting on the results of an initial trial with Aradigm's SmartMist hand-held, breath-actuated, microprocessor-controlled metered dose inhaler. The device analyses the inspiratory flow profile and inhaled volume, and activates an aerosol from the MDI when pre-defined levels of the two criteria are reached.
The study, said Dr Farr, showed that the device is in an ideal platform for investigating the effects of various inhalation modes on the delivery of medications, actuating the MDI only when inhalation has reached a specific flow and volume.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze